Loading
Life sciences · Journal article
Theoretical and Natural Science · September 29, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Monoclonal antibodies (mAbs) are a cornerstone of cancer therapy. They offer high target specificity and diverse cytotoxic mechanisms, which render them superior to many conventional cytotoxic treatments. This review examines therapeutic mAbs from two aspects. First, their mechanisms of action are analysed, including direct target modulation (signaling inhibition and ADC payload delivery), Fc‑mediated effector functions (ADCP, ADCC, and CDC), and immune checkpoint blockade (CTLA-4, PD-1/PD-L1, LAG-3, and TIM-3 pathways). In addition, engineering strategies that potentiate these effects are considered as well, such as Fc modification and optimised linker‑payload design for antibody-drug conjugates. Second, the clinical landscape of approved mAbs is reviewed. Their remarkable success in hematologic malignancies (anti-CD20, anti-CD33, anti-CD38) are compared with the greater challenges in solid tumors, where tumour heterogeneity, immunosuppressive microenvironments and primary resistance frequently limit therapeutic efficacy. In solid tumours, biomarker-driven agents (anti-HER2, anti-EGFR) and immune checkpoint inhibitors are central. Immune-related adverse events also represent an important safety concern for checkpoint-blocking antibodies. It is critical to understand these mechanisms and clinical outcomes before optimizing current therapies and guiding next-generation antibody development, including novel ADCs and bispecific antibodies.